A phase Ib study of sapacitabine and olaparib in patients with BRCA1/2-mutated metastatic breast cancer. Lynce F, Graham N, Kochupurakkal BS, Nguyen H, et al. Clin Cancer Res 2025 Dec 3. doi: 10.1158/1078-0432.CCR-25-0571.

Read + Share

Amedeo Smart

Independent Medical Education

Lynce F, Graham N, Kochupurakkal BS, Nguyen H, et al. A phase Ib study of sapacitabine and olaparib in patients with BRCA1/2-mutated metastatic breast cancer. Clin Cancer Res 2025 Dec 3. doi: 10.1158/1078-0432.CCR-25-0571.
PMID: 41335237